Johnson & Johnson's Rybrevant Faspro Receives U.S. FDA Priority Review as Potential First-In-Class EGFR- and MET-Targeted Subcutaneous Treatment for Advanced Head and Neck Cancer
July 31, 2026
July 31, 2026
RARITAN, New Jersey, July 31 -- Johnson and Johnson Innovative Medicine issued the following news release on July 30, 2026:
* * *
Johnson & Johnson's RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metas . . .
* * *
Johnson & Johnson's RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metas . . .